ISSN: 0264-410X

Journal Home

Journal Guideline

Vaccine Q1 Unclaimed

Elsevier BV Netherlands

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Vaccine is a journal indexed in SJR in Infectious Diseases and Molecular Medicine with an H index of 191. It has a price of 2395 €. It has an SJR impact factor of 1.392 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1.392.

Vaccine focuses its scope in these topics and keywords: vaccine, influenza, vaccination, virus, recombinant, vaccines, immunization, responses, protein, response, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Immunology and Microbiology (miscellaneous) (Q1) Infectious Diseases (Q1) Molecular Medicine (Q1) Public Health, Environmental and Occupational Health (Q1) Veterinary (miscellaneous) (Q1)

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1.392

SJR Impact factor

191

H Index

1034

Total Docs (Last Year)

3272

Total Docs (3 years)

38560

Total Refs

13154

Total Cites (3 years)

3051

Citable Docs (3 years)

3.84

Cites/Doc (2 years)

37.29

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Reviews Microbiology Q1
Clinical Microbiology Reviews Q1
Journal of Infection Q1
The Lancet HIV Q1
Clinical Infectious Diseases Q1

Compare this journals

Aims and Scope

Best articles by citations

Alkyl-polyacrylate esters are strong mucosal adjuvants

The influence of host factors and immunogenetics on lymphocyte responses to HepageneS vaccination

A look at new models to support vaccine research and development

Teenagers' lifestyle and the risk of exposure to hepatitis B virus

Predictive value of pre-clinical work for vaccine safety assessment

Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids*1

Maternal immunization: the influence of liability issues on vaccine development

Analysis of factors influencing vaccine uptake from various perspectives

Analysis of factors influencing vaccine uptake: perspective from Spain

Analysis of factors influencing vaccine uptake: perspectives from Belgium

Regulating vaccines involving new technologies to ensure safety and timely licensure - the challenge

Pneumococcal infections in New Zealand

SHOW MORE ARTICLES

The antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens

Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply

Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model

Induction of mucosal immunity with a replication-defective adenoviral recombinant

DNA pulsed macrophage-mediated cDNA expression library immunization in vaccine development

The medical scientist working with the media for the public good

How to improve communication on vaccine issues at the national level?

How to improve communication on vaccine safety at international level?

Statistical assessment of the association between vaccination and rare adverse events post-licensure

Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

Perception of risk of vaccine adverse events: a historical perspective